-
Mashup Score: 1
TO THE EDITOR:
Source: American Society of HematologyCategories: Hematologists1, Latest HeadlinesTweet
-
Mashup Score: 2Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy - 2 year(s) ago
Key Points. Patients without detectable lymphoma at the time of CD19 CAR T-cell therapy had excellent outcomes.Administering CD19 CAR T-cell to patients without
Source: American Society of HematologyCategories: Hematologists1, Latest HeadlinesTweet
-
Mashup Score: 7
Oral and Poster Abstracts Oral Session: 705. Cellular Immunotherapies: Results from CD19-Directed CAR T in treating Aggressive B-cell Lymphomas Sunday, December 11, 2022: 5:15 PM Hall E (Ernest N. Morial Convention Center) Gloria Iacoboni, MD1*, ANA Africa Martin Lopez2*, Katarzyna Aleksandra Jalowiec3*, Mi Kwon, MD, PhD4*, Kai Rejeski, MD5, Víctor Navarro Garcés6*,…
Source: ash.confex.comCategories: Hematologists1, Latest HeadlinesTweet
-
Mashup Score: 1
Oral and Poster Abstracts Oral Session: 627. Aggressive Lymphomas: Clinical and Epidemiological: Treatment of CNS Lymphoma, Neurologic Toxicities, and Relapsed/Refractory DLBCL Saturday, December 10, 2022: 1:00 PM New Orleans Theater C (Ernest N. Morial Convention Center) Gloria Iacoboni, MD1*, Josu Iraola-Truchuelo2*, Alberto Mussetti3*, Paula Fernández-Caldas4*,…
Source: ash.confex.comCategories: Hematologists1, Latest HeadlinesTweet
-
Mashup Score: 1Toxicity and Efficacy of CAR T-cell Therapy in PCNSL and SCNSL: A Meta-Analysis of 128 Patients - 2 year(s) ago
Relapsed/refractory primary and secondary central nervous system lymphomas (PCNSL, SCNSL) are associated with short survival and represent an unmet need, requir
Source: American Society of HematologyCategories: Hematologists1, Latest HeadlinesTweet
-
Mashup Score: 2Outcomes of CD19 targeted CAR T-cell Therapy for Patients with Reduced Renal Function Including Dialysis - 2 year(s) ago
Patients with renal impairment (RI) are typically excluded from trials evaluating chimeric antigen receptor (CAR) T-cell therapies. We evaluated the o…
Source: www.sciencedirect.comCategories: Hematologists1, Latest HeadlinesTweet
-
Mashup Score: 2Impact of Cytomegalovirus Replication in Patients with Aggressive B-Cell Lymphoma Treated with CAR T-Cell Therapy - 2 year(s) ago
Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the management of patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL)1–5. Based on the results of the phase 2 pivotal trials ZUMA-1, JULIET and TRANSCEND, three CD19-targeted CAR T-cell products are approved by the Food and Drug Administration (FDA) and European Medicines Agency (EMA) for patients with R/R LBCL,…
Categories: Hematologists1, Latest HeadlinesTweet
-
Mashup Score: 3Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapy - Nature Medicine - 2 year(s) ago
Single-cell proteomic profiling of circulating CAR T cells in patients treated with CD19-CAR shows that CD4+Helios+ CAR T cells on day 7 after infusion are associated with progressive disease and less severe neurotoxicity.
Source: NatureCategories: Hematologists1, Latest HeadlinesTweet
-
Mashup Score: 8Hematopoietic stem cell boost for persistent neutropenia after CAR-T cell therapy: a GLA/DRST study - 2 year(s) ago
Key Points. Hematopoietic stem cell boosts for persistent neutropenia showed recovery or sustained neutrophil improvement in 84% of patientsHematopoietic stem c
Source: American Society of HematologyCategories: Hematologists1, Latest HeadlinesTweet
-
Mashup Score: 3
Key Points. We emphasized the potential critical role of CD58 loss in resistance to CAR T-cell therapy.Loss of CD58 caused inefficient IS formation with CAR T c
Source: American Society of HematologyCategories: Hematologists1, Latest HeadlinesTweet
RT @smbenlazar: CAR T-cell therapy for mantle cell lymphoma with central nervous system relapse https://t.co/0JGUFHmHd4 #lymsm https://t.co…